Ascendis Pharma AS (NAS:ASND)
$ 124.33 -2.22 (-1.75%) Market Cap: 7.43 Bil Enterprise Value: 7.88 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Ascendis Pharma A/S at Wedbush PacGrow Healthcare Virtual Conference Transcript

Aug 11, 2020 / 06:20PM GMT
Release Date Price: $140.49 (-1.93%)
Vasiliana Vireen Moussatos
Wedbush Securities Inc., Research Division - MD of Equity Research

Thank you very much for joining us at the 2020 Virtual Wedbush Healthcare Conference. My name is Liana Moussatos, and I'm one of the senior health care analysts at Wedbush. It's my pleasure to introduce Ascendis Pharma.

Today, we are joined by the CEO, Jan Mikkelsen; and the CFO, Scott Smith. Thank you for joining us. We will start with a fireside chat, and then we'll transition to Q&A. (Operator Instructions)

Jan and Scott, please provide a quick overview of TransCon technology.

Jan MÃ;ller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director

¸ - /- -

Thanks, Liana. It's a pleasure to be part of this virtual show here now, and we always would like to come back to a life where we can meet face-to-face, but I think we even really function pretty well in this way here.

And going back to the TransCon technology. TransCon technology basically

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot